27.11.2012 Views

BioWorld® - Medical Device Daily

BioWorld® - Medical Device Daily

BioWorld® - Medical Device Daily

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

BioWorld Industrial Biotechnology StatReport: Immediate and Comprehensive Industry Information<br />

Microvascular<br />

Systems, MPS<br />

(IGI)<br />

Millennium<br />

Pharmaceuticals<br />

Inc.<br />

liposome formulations<br />

for injectable animal<br />

vaccines<br />

Mitokor Inc. target and drug<br />

discovery in certain<br />

neurodegenerative<br />

development<br />

agreement<br />

fungal diseases research, licensing,<br />

and product<br />

development<br />

agreement (3/95),<br />

expanded--<br />

Millennium to add<br />

research personnel<br />

to focus on<br />

application of<br />

transcript profiling<br />

and ultra-highthroughput<br />

screening<br />

diseases<br />

Moleculon Poroplastic controlledrelease<br />

disc used in<br />

Paratect antiparasitic<br />

Monogram<br />

Biosciences Inc.<br />

bolus system<br />

Monogram's HIV Co-<br />

Receptor Tropism<br />

Assay to be made<br />

available globally<br />

drug discovery based<br />

Myco<br />

Pharmaceuticals on genomics technology<br />

NAEJA<br />

Pharmaceutical<br />

Inc.<br />

Neogen Corp. immunoassay<br />

diagnostic kits for the<br />

poultry industry<br />

Neurogen Corp. drugs to treat obesity<br />

and eating disorders<br />

Copyright ©2006 AHC Media ® 312<br />

9/87<br />

12/97<br />

technologies<br />

R&D agreement 1998<br />

manufacturing<br />

agreement<br />

nonexclusive<br />

collaboration<br />

agreement<br />

5/06<br />

R&D agreement 3/95<br />

anti-infectives contract research<br />

agreement<br />

development and<br />

supply agreements<br />

three- to five-year<br />

joint R&D<br />

agreement--Pfizer<br />

to receive<br />

worldwide exclusive<br />

license to market<br />

any drugs<br />

developed through<br />

the collaboration<br />

and to fund<br />

Neurogen's R&D<br />

program. Neurogen<br />

will retain option to<br />

manufacture the<br />

products for NAFTA<br />

countries.<br />

Neurogen will retain<br />

a profit-sharing<br />

option for NAFTA<br />

countries (11/95).<br />

funded research<br />

portion extended for<br />

one year beginning<br />

in 11/98<br />

3/01<br />

8/92<br />

5/98

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!